Skip to main content
. Author manuscript; available in PMC: 2014 Apr 1.
Published in final edited form as: J Hypertens. 2013 Apr;31(4):820–829. doi: 10.1097/HJH.0b013e32835e8227

FIGURE 2.

FIGURE 2

Effect of salt intake and fenofibrate on mean arterial pressure (MAP), SBP and DBP. Changes from low salt to high salt intake and placebo (ΔPla-Low), from low salt to high salt intake and fenofibrate (ΔFeno-Low), and during high salt and fenofibrate compared with high salt intake and placebo (ΔFeno-Pla) are indicated. Volunteers were classified as salt-sensitive if their MAP was at least 5 mmHg higher during high salt and placebo compared with during low salt intake. Panel (d) shows the effect of fenofibrate treatment on SBP during high salt intake (Δ SBPFeno-Pla) as a function of salt sensitivity of blood pressure defined as the difference in MAP between low salt and high salt intake during placebo (Δ MAPPla-Low). Grey filled circles indicate those volunteers defined as salt-sensitive.